AUTHOR=Koomdee Napatrupron , Pratoomwun Jirawat , Jantararoungtong Thawinee , Theeramoke Voralaksana , Tassaneeyakul Wichittra , Klaewsongkram Jettanong , Rerkpattanapipat Ticha , Santon Siwalee , Puangpetch Apichaya , Intusoma Utcharee , Tempark Therdpong , Deesudchit Tayard , Satapornpong Patompong , Visudtibhan Anannit , Sukasem Chonlaphat 

TITLE=Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population

JOURNAL=Frontiers in Pharmacology

VOLUME=8

YEAR=2017

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2017.00879

DOI=10.3389/fphar.2017.00879

ISSN=1663-9812

ABSTRACT=<p><bold>Background:</bold> Lamotrigine (LTG) is commonly used for treatment of epilepsy and bipolar disorder. It is one of the common cause of cutaneous adverse drug reactions (CADR). Clinical symptoms of LTG-induced CADR range from maculopapular exanthema (MPE) to severe cutaneous adverse reactions (SCAR). This study aimed to determine the association of the LTG-induced CADR with human leukocyte antigen (<italic>HLA</italic>) alleles in Thai patients.</p><p><bold>Methods:</bold> Fifteen patients with LTG-induced CADR [10 MPE; 4 Stevens–Johnson syndrome; and 1 drug reaction with eosinophilia and systemic symptoms] and 50 LTG-tolerant controls were included in the study. <italic>HLA-A</italic> and <italic>HLA-B</italic> genotyping was performed using polymerase chain reaction-sequence-specific oligonucleotides probes.</p><p><bold>Results:</bold> The proportion of <italic>HLA-A<sup>∗</sup>02:07</italic> and <italic>HLA-B<sup>∗</sup>15:02</italic> allele carriers were significantly higher in the LTG-induced CADR group than in the tolerant controls [odds ratio (OR): 7.83; 95% confidence interval (CI): 1.60–38.25; <italic>P</italic> = 0.013, and OR: 4.89; 95% CI: 1.28–18.67; <italic>P</italic> = 0.014]. In addition, subjects with <italic>HLA-A<sup>∗</sup>33:03</italic>, <italic>HLA-B<sup>∗</sup>15:02</italic>, and <italic>HLA-B<sup>∗</sup>44:03</italic> were significantly higher in the LTG-induced MPE group than in the tolerant controls (OR: 8.27; 95% CI: 1.83–37.41; <italic>P</italic> = 0.005, OR: 7.33; 95% CI: 1.63–33.02; <italic>P</italic> = 0.005; and OR: 10.29; 95% CI: 1.45–72.81; <italic>P</italic> = 0.029). In contrast to the LTG-induced MPE group, there were no significant differences between <italic>HLA</italic> alleles and LTG-induced SCAR group.</p><p><bold>Conclusion:</bold><italic>HLA-A<sup>∗</sup>02:07</italic> and <italic>HLA-B<sup>∗</sup>15:02</italic> were associated with LTG-induced CADR in Thai patients. We also identified an association between <italic>HLA-A<sup>∗</sup>33:03</italic>, <italic>HLA-B<sup>∗</sup>15:02</italic>, and <italic>HLA-B<sup>∗</sup>44:03</italic> and LTG-induced MPE in this population. These results suggest that these alleles could be useful screening markers for preventing CADR before LTG treatment in Thai patients, but further replication studies with larger sample sizes are needed.</p>